106 related articles for article (PubMed ID: 25326842)
1. [Safety and tolerability of GLP-1 receptor agonists].
Soldevila B; Puig-Domingo M
Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
[TBL] [Abstract][Full Text] [Related]
2. [Safety and tolerability of GLP-1 receptor agonists].
Soldevila B; Puig-Domingo M
Med Clin (Barc); 2014 Sep; 143 Suppl 2():35-40. PubMed ID: 25437464
[TBL] [Abstract][Full Text] [Related]
3. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
4. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
Russell-Jones D
Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
[TBL] [Abstract][Full Text] [Related]
5. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
6. Adverse Effects of GLP-1 Receptor Agonists.
Filippatos TD; Panagiotopoulou TV; Elisaf MS
Rev Diabet Stud; 2014; 11(3-4):202-30. PubMed ID: 26177483
[TBL] [Abstract][Full Text] [Related]
7. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
Peng H; Want LL; Aroda VR
Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
[TBL] [Abstract][Full Text] [Related]
8. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
Raccah D
Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
[TBL] [Abstract][Full Text] [Related]
10. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
11. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
12. GLP-1R agonist therapy for diabetes: benefits and potential risks.
Samson SL; Garber A
Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
[TBL] [Abstract][Full Text] [Related]
13. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
Liu Y; Tian Q; Yang J; Wang H; Hong T
Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
Chalmer T; Almdal TP; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
[TBL] [Abstract][Full Text] [Related]
17. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
19. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
Kmietowicz Z
BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
[No Abstract] [Full Text] [Related]
20. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
